CT-SCOUT App Markedly Improves Enrollment Rates for IBD Trials, Developer Says

CT-SCOUT App Markedly Improves Enrollment Rates for IBD Trials, Developer Says
5
(1)

Patient recruitment rates in recent international inflammatory bowel disease (IBD) clinical trials increased markedly when the CT-SCOUT digital solution was used, the technology’s developer announced.

The French start-up company Clinical Trials Mobile Application (CTMA) presented two scientific posters outlining results of its innovative platform during the recent annual meeting of the European Crohn’s and Colitis Organization (ECCO) in Vienna, Austria.

The multi-device technology is based on a unique algorithmic model that addresses patient attrition.

Currently used in 10 countries and 150 centers, the pre-screening web application enables physicians to detect in real time patients eligible for ongoing clinical trials, and quickly and easily facilitates research team coordination.

The overarching idea is that increased patient recruitment will reduce the duration of clinical trials, ultimately leading to more treatment options sooner and at less cost. The tool is touted as the missing link between study sponsors and clinical sites.

According to a CTMA press release, in a prospective, open-label, observational and comparative investigation involving 644 patients at 134 sites in six countries, sites that used CT-SCOUT experienced a 2.8-fold randomization rate increase over those that didn’t. The randomization rate in ulcerative colitis patients was four times higher, and 1.9-times more for those with Crohn’s disease. (In clinical trials, randomization is the process of assigning patients by chance to groups that receive different treatments.)

In a Phase 3 IBD study in France, sites using the tool randomized “significantly” more patients than those not equipped with the technology, the company said. Sites equipped with CT-SCOUT’s Premium mode, which includes all app functions, recorded 4.5-times more randomization than those not equipped, and 1.6-times more than those using the Freemium mode and its limited app functions.

“The main barrier to validating new molecules in the field of IBD is insufficient patient enrollment in clinical trials, resulting in premature termination of trials and increased costs,” said Laurent Peyrin-Biroulet, ECCO president. “CT-SCOUT is important for patients because it facilitates their enrollment in clinical trials. Before CT-SCOUT we missed out on a lot of patients. We now have dramatically increased enrollments into our studies.”

Based on a unique algorithm, CT-SCOUT is tailored to each center, improving the accuracy and time effectiveness of pre-screening activities. It includes each site’s academic and industry-sponsored studies, and reminds on-site healthcare professionals of recruitment activities and relevant elements. Clinicians have immediate access to patient data.

“In recent international prospective observational IBD trials, patient recruitment tripled in centers equipped with the CTMA solution, compared to unequipped centers,” said Norman Sabbah, CTMA chief operating officer. “CTMA stands out from the competition because its technology is based on a unique algorithm. It offers all the studies on one platform, along with a research team coordination system and a dashboard that gives sponsors visibility on the center’s activity in terms of patient recruitment.”

IBD affects some 5 million individuals worldwide.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 455
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • takeda research collaboration
  • CT-SCOUT app studied
  • gut microbes
  • Genedata

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?